☆ 4.6 Article

Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial

PLOS MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Article Rheumatology

Expression of interleukin-6 in synovial tissue of patients with polymyalgia rheumatica

William F. Jiemy et al.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Article Rheumatology

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

Christina Charles-Schoeman et al.

Summary: This post hoc analysis observed a higher risk of MACE associated with tofacitinib compared to TNFi in RA patients with a history of ASCVD. Among patients without a history of ASCVD but with prevalent CV risk factors, there does not appear to be a difference in MACE risk between tofacitinib 5 mg twice daily and TNFi, although any absolute risk excess is likely low.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Article Rheumatology

Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a phase 2 study

Le Zhang et al.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Review Immunology

Immune system activation in polymyalgia rheumatica: Which balance between autoinflammation and autoimmunity? A systematic review

Elvis Hysa et al.

Summary: This study systematically reviewed the immune system activation mechanisms in polymyalgia rheumatica (PMR) and found that both the innate and adaptive immune systems play important roles in its pathogenesis and disease progression. The results showed that there are abnormalities in the innate immune system of PMR patients, and cytokines such as interleukin-6 play a key role in the disease process. The adaptive immune system also undergoes changes, including T cell polarization, immunosenescence, and downregulated immune regulatory response. The study also found an interaction between the innate and adaptive immune systems. Although several autoantibodies have been detected in PMR patients, they do not seem to correlate with disease activity.

AUTOIMMUNITY REVIEWS (2022)

Add to Collection

Article Medicine, General & Internal

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

Steven R. Ytterberg et al.

Summary: In this trial comparing the use of tofacitinib with a TNF inhibitor in a cardiovascular risk-enriched population, the risks of major adverse cardiovascular events (MACE) and cancers were found to be higher with tofacitinib, and it did not meet noninferiority criteria. Several adverse events were more common with tofacitinib.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Rheumatology

Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial

Michael Bonelli et al.

Summary: In patients with newly diagnosed polymyalgia rheumatica undergoing rapid glucocorticoid tapering, tocilizumab showed superior effectiveness compared to placebo in achieving sustained glucocorticoid-free remission, longer time to relapse, and lower cumulative glucocorticoid dose.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Editorial Material Medicine, General & Internal

Tocilizumab as a Novel Therapy for Steroid-Dependent Polymyalgia Rheumatica

Brendan Antiochos

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Article Medicine, General & Internal

Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy A Randomized Clinical Trial

Valerie Devauchelle-Pensec et al.

Summary: This study compared the efficacy of tocilizumab vs placebo in patients with glucocorticoid-dependent polymyalgia rheumatica. The results showed that tocilizumab group had significantly better outcomes in the primary and 11 secondary endpoints at 24 weeks compared to the placebo group.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Review Immunology

Predicting the risk of relapse in polymyalgia rheumatica: novel insights

Diana Prieto-Pena et al.

Summary: Relapses are common in PMR, especially when the prednisone dose is below 5-7.5 mg/day. The speed of glucocorticoid tapering is considered a key factor influencing the development of relapses in isolated PMR. Genetic factors, such as HLA-DRB1*0401 alleles, may also increase the risk of relapse. Biomarkers like elevated levels of angiopoietin-2 may indicate a poor prognosis in PMR. Methotrexate and tocilizumab may be necessary for PMR patients with multiple relapses.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Immunology

SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation

Bingyu Yan et al.

Summary: Patients with COVID-19 present a wide range of acute clinical manifestations, affecting the lungs, liver, kidneys, and gut. Research has found that SARS-CoV-2 infection induces high activation of the complement system intracellularly in respiratory epithelial cells, with distinct complement activation signatures in cells from patients. Combination therapy with JAK inhibitors and drugs that normalize NF-kappa B signaling could potentially have clinical application for severe COVID-19 patients, by inhibiting C3a production.

SCIENCE IMMUNOLOGY (2021)

Add to Collection

Meeting Abstract Rheumatology

BARICITINIB IN POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS: REPORT OF SIX CASES

D. Camellino et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

IL6 inhibition of inflammatory S100A8/9 proteins is NF-κB mediated in essential thrombocythemia

Milos Diklic et al.

CELL BIOCHEMISTRY AND FUNCTION (2020)

Add to Collection

Article Cell Biology

Cigarette smoke-induced lung inflammation in COPD mediated via CCR1/JAK/STAT/NF-κB pathway

Kaishun Zhao et al.

AGING-US (2020)

Add to Collection

Review Rheumatology

Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica

Dario Camellino et al.

NATURE REVIEWS RHEUMATOLOGY (2020)

Add to Collection

Editorial Material Medicine, General & Internal

Polymyalgia Rheumatica and Giant Cell Arteritis

Frank Buttgereit et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study

Mar Pujades-Rodriguez et al.

PLOS MEDICINE (2020)

Add to Collection

Article Immunology

The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle

Guillermo Carvajal Alegria et al.

AUTOIMMUNITY REVIEWS (2020)

Add to Collection

Article Oncology

IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma

Giulia Biffi et al.

CANCER DISCOVERY (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis

Hui Zhang et al.

CIRCULATION (2018)

Add to Collection

Review Rheumatology

Pathogenesis of polymyalgia rheumatica

G. Guggino et al.

REUMATISMO (2018)

Add to Collection

Review Rheumatology

Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities

Christian Dejaco et al.

NATURE REVIEWS RHEUMATOLOGY (2017)

Add to Collection

Article Multidisciplinary Sciences

Formal Modelling of Toll like Receptor 4 and JAK/STAT Signalling Pathways: Insight into the Roles of SOCS-1, Interferon-β and Proinflammatory Cytokines in Sepsis

Rehan Zafar Paracha et al.

PLOS ONE (2014)

Add to Collection

Article Rheumatology

2012 Provisional Classification Criteria for Polymyalgia Rheumatica A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative

Bhaskar Dasgupta et al.

ARTHRITIS AND RHEUMATISM (2012)

Add to Collection

Article Rheumatology

Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis

Maxime Samson et al.

ARTHRITIS AND RHEUMATISM (2012)

Add to Collection

Article Rheumatology

Increased Muscle Interstitial Levels of Inflammatory Cytokines in Polymyalgia Rheumatica

Frederik Kreiner et al.

ARTHRITIS AND RHEUMATISM (2010)

Add to Collection

Article Biochemistry & Molecular Biology

C/EBPδ and STAT-1 Are Required for TLR8 Transcriptional Activity

Claudia Zannetti et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2010)

Add to Collection

Review Cell Biology

Crosstalk among Jak-STAT, toll-like receptor, and ITAM-dependent pathways in macrophage activation

Xiaoyu Hu et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2007)

Add to Collection

Article Rheumatology

A disease activity score for polymyalgia rheumatica

BF Leeb et al.

ANNALS OF THE RHEUMATIC DISEASES (2004)

Add to Collection

Article Cardiac & Cardiovascular Systems

The regulation of EN-RAGE (S100A12) gene expression in human THP-1 macrophages

T Hasegawa et al.

ATHEROSCLEROSIS (2003)

Add to Collection

Article Rheumatology

Chemokine receptor expression and in vivo signaling pathways in the joints of rats with adjuvant-induced arthritis

S Shahrara et al.

ARTHRITIS AND RHEUMATISM (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.